IGI Laboratories is a specialty generic drug development and manufacturing company. Our mission is to be a leading player in the specialty generic prescription drug market •Total revenues of $6.5 million in the second quarter of 2014, an increase of 70% over the same quarter in 2013 •Total revenues of $13.3 million for the six months ended June 30, 2014, an increase of 78% over the same period in 2013 •Total revenues generated from the sale of IGI label generic topical pharmaceutical products for the three and six months ended June 30, 2014 were $3.4 million, and $6.3 million, respectively, increases of 146% and 127% over the same periods in 2013, respectively •Gross margin increased to 43% for the six months ended June 30, 2014 from 30% in the same period of 2013
dommage d'avoir manquer les progres avant
il se pose la question : est-il trop tard ?
pour investir peut-etre, mais pas pour le swingers
ligne de trend fort 22/8 a 5.75, 5/9 a 6.75, 15/9 a 7.15